Adaptimmune Therapeutics (ADAP) Tops Q2 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Adaptimmune Reports Second Quarter 2016 Financial Results
August 8, 2016 7:00 AM EDTÂ - Conference call to be held today at 8:00 AM ET (1:00 PM BST) -
PHILADELPHIA and OXFORD, United Kingdom, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP) (Adaptimmune or the Company), a leader in T-cell therapy to treat cancer, today reported financial results for the second quarter ended June 30, 2016.
Recent Corporate and Clinical Highlights:
Received access to Priority Medicines (PRIME) regulatory support from the European Medicines Agency for NY-ESO SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapy;Received orphan medicinal product designation for... More